drugset / Trial / NCT04592640

Human Amniotic-Derived Mesenchymal Stem Cell Therapy for Calciphylaxis

NCT04592640 ↗

NaSingle-groupOpen-labelTreatment

Summary

Treatment for Calciphylaxis Patients with Human Amniotic-derived Mesenchymal Stem Cells

Timeline

Start
2018-09-17
Primary completion
2027-09-17
Completion
2028-09-17

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Human amniotic-derived mesenchymal stem cells Cell therapy 20000 unknown Intravenous
Subject Human amniotic-derived mesenchymal stem cells Cell therapy 1e+06 cells/kg Intravenous